MedTrace Logo

Real World Effectiveness of Eptinezumab in Participants With Migraine

NCT05284019 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-05-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.

Conditions

Interventions

DRUG

Eptinezumab

Concentrate for solution for IV infusion

DRUG

Erenumab

Solution for SC Injection

DRUG

Onabotulinumtoxin-A

Solution for IM Injection

DRUG

Fremanezumab

Solution for SC Injection

DRUG

Galcanezumab

Solution for SC Injection

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2023-02-17
Completion
2023-04-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05284019 on ClinicalTrials.gov